
Heather Burnett, MSc
Co-Founder & Principal ConsultantHeather Burnett has more than 15 years of experience in health economics and outcomes research (HEOR), supporting the development of early- and late-stage HEOR strategies and evidence packages required by drug manufacturers for health technology assessment (HTA) submissions. She specializes in evidence synthesis, including systematic and targeted literature reviews of both quantitative and qualitative evidence, meta-analysis, network meta-analysis, population-adjusted indirect comparisons, and trial-level surrogate endpoint analyses. She has led multi-workstream programs spanning value dossiers, literature reviews, indirect treatment comparisons (ITCs) and economic models. Her research has supported regulatory submissions and HTA evaluations, and she has authored more than 60 publications. Her therapeutic area experience spans hematology, immune-mediated, respiratory, cardiovascular and infectious diseases, and vaccines. Her recent work focuses on comparative effectiveness evidence strategy and planning, including for EU Joint Clinical Assessments (JCA), and on how artificial intelligence can surface insights earlier in the evidence synthesis workflow. She holds an MSc in Health Policy, Management and Evaluation from the University of Toronto, and an MSc in Molecular and Cellular Biology and a BSc from the University of Guelph.
LinkedIn →

